Shamloo Lab News
Workshop on Neurobehavior
The Workshop is a week-long, in-person, interactive course on practical, mechanistic, and ethological aspects of behavioral phenotyping, with emphasis on applications for neurodegenerative disease models and drug discovery.
Learn more and sign up here.
SPrINT Pilot Project Program 2022
The Stanford Program for Integrated Neuroscience Technologies (SPrINT), in collaboration with the NIH Brain Initiative, is calling for proposals for Pilot Projects. Projects that are selected will be fully conducted by SPrINT staff and data and/or tissues provided to applicants. We encourage project proposals that are highly innovative and that integrate a combination of behavior, genetics, viral technologies, imaging, and/or brain organogenesis techniques. Guidelines and Selection Criteria are indicated below.
We are pleased to announce that CuraSen Therapeutics Inc, a Stanford originated Biotech founded by Dr. Mehrdad Shamloo in 2017, has successfully closed $54.5 Million Series A Financing. CuraSen Therapeutics Inc. is developing drugs targeting a novel mechanism in CNS disorders with ultimate goal of improving the quality of life of people with neurodegenerative disorders. Additional co-founders include Robert Booth, PhD, former chief executive officer of ViroBay, along with Anthony Ford, PhD, chief executive officer, CuraSen and Ms. Kathleen Sereda Glaub, executive chair, CuraSen. For more information, visit www.curaseninc.com.
Read More: